Hjem › Nyrekancer › Arizona
Nyrekancer kliniske forsøg i Arizona
8 studier for Nyrekancer søger deltagere på steder i Arizona.
Byer i Arizona
Officiel studietekst (engelsk)
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- University of Arizona Cancer Center, Tucson
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06234605Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Research Site, Gilbert
- Research Site, Goodyear
- Research Site, Phoenix
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT07011719Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Banner Health, Gilbert
- Mayo Clinic Hospital, Phoenix
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT04981119Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Mayo Clinic Building- Phoenix, Phoenix
- Mayo Clinic Arizona, Scottsdale
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT07227415Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Phoenix
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 3. aug. 2026 · NCT05433142KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Mayo Clinic Comprehensive Cancer Center, Phoenix
- University of Arizona, Tucson
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 8. jun. 2026 · NCT06026410SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Scottsdale
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- Banner MD Anderson Cancer Center, Gilbert
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2025 · NCT06682793Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.